melphalan has been researched along with pimonidazole* in 2 studies
2 other study(ies) available for melphalan and pimonidazole
| Article | Year |
|---|---|
Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.
A cell line, CHO-Chlr, which has elevated levels of glutathione-S-transferase (GST), is resistant to damage caused by bi-functional nitrogen mustards. This cell line has a similar radiation sensitivity to and value of oxygen enhancement ratio as the wild type cells, CHO-K1, from which the mutant line was derived. Hypoxic cell radiosensitizing efficiencies for misonidazole, etanidazole (SR2508), and pimonidazole (R0 03-8799) are similar in both cell lines with values for C1.6 of 0.5, 0.75, and 0.08 mmol dm-3 for each drug respectively. In contrast, for RSU 1069 the sensitizing efficiency is lower in the cell line showing elevated levels of GST. The hypoxic toxicity of RSU 1069 and misonidazole is similar in each cell line, whereas in air, toxicity is 2 fold less in the CHO-Chlr cells. These results suggest that reaction of the alkylating aziridine part of RSU 1069 contributes to the high sensitizing efficiency of this drug. This is likely to be a consequence of either binding of the sensitizing moiety at the target site (ie, increased local concentration or induction of sub-lethal damage that is only expressed on subsequent irradiation. Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Etanidazole; Glutathione Transferase; Melphalan; Misonidazole; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents | 1989 |
A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
The abilities of misonidazole, Ro 05-9963, Ro 03-8799 and Sr-2508 to enhance the action of the drugs cyclophosphamide (CY) and melphalan (L-PAM) have been compared in two mouse fibrosarcomas at acute and chronic sensitizer doses. SR-2508 was not effective with either CY or L-PAM in either tumor. Some enhancement of CY was obtained with Ro 05-9963 and Ro 03-8799; however, the degree of enhancement varied according to tumor and acute or chronic sensitizer dose. In all cases, the degree of enhancement was less than that obtained with an equivalent dose of misonidazole in both tumor systems. Of the four compounds tested, MISO would appear to have the most potential as a chemosensitizer. Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Etanidazole; Fibrosarcoma; Melphalan; Mice; Mice, Inbred CBA; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents | 1984 |